Aldeyra Therapeutics, Inc. insider trading
Every open-market purchase and sale by Aldeyra Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Aldeyra Therapeutics, Inc.’s insiders pay?
From August 7, 2014 to June 5, 2026, 17 insiders reported 48 open-market purchases and 9 sales not made under a pre-set plan in Aldeyra Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −4.3% against the S&P 500 on average (median +3.9%), over 38 purchases with a full year of prices; 58% beat the index. After sales, the shares moved −45.0% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on October 23, 2015 into $3,029 by November 2, 2026, −10.3% a year. It held shares 76% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $35,728 (+12.3% a year), and held throughout $43,607 (+14.3%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Perceptive Life Sciences Master Fund Ltd | 10% owner | 10 | −11.7% (7) | 29% | 2 | — | April 7, 2025 |
| Brady Todd C | President and CEO | 9 | +12.6% (7) | 100% | 1 | — | June 5, 2026 |
| Perceptive Advisors LLC | 10% owner | 8 | −9.3% (8) | 50% | 0 | — | August 11, 2022 |
| Douglas Richard | Director | 6 | +13.0% (4) | 100% | 0 | — | March 20, 2026 |
| Edelman Joseph | 10% owner | 5 | −31.1% (4) | 25% | 0 | — | April 8, 2024 |
| Machatha Stephen | Chief Development Officer | 0 | — | — | 3 | −51.1% (2) | August 13, 2025 |
| Greenberg Bruce | See Remarks | 0 | — | — | 2 | −10.5% (1) | August 14, 2024 |
| Joyce Martin Joseph | Director | 2 | +32.3% (1) | 100% | 0 | — | June 27, 2022 |
| Alfieri Michael | Principal Financial Officer | 1 | −91.8% (1) | 0% | 0 | — | August 15, 2025 |
| Bronstein Ben | Director | 1 | +32.3% (1) | 100% | 0 | — | February 21, 2017 |
| Clark David J | Chief Medical Officer | 1 | +4.5% (1) | 100% | 0 | — | September 10, 2019 |
| Clarke C. Boyd | Director | 1 | — | — | 0 | — | August 7, 2014 |
| Mcmullin David | Chief Commerical Officer | 1 | −0.7% (1) | 0% | 0 | — | September 9, 2019 |
| Miller-Rich Nancy | Director | 1 | −28.7% (1) | 0% | 0 | — | October 21, 2024 |
| Reed Joshua | Chief Financial Officer | 1 | −0.7% (1) | 0% | 0 | — | September 9, 2019 |
| Treu Jesse I | Director | 0 | — | — | 1 | −67.5% (1) | March 28, 2019 |
| Tulipano Stephen J | Chief Financial Officer | 1 | +32.3% (1) | 100% | 0 | — | February 21, 2017 |
When several insiders traded Aldeyra Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Aldeyra Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −29.6% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 29, 2021 | 2 buying | −0.9% | −39.8% | −90.4% |
| September 30, 2019 | 5 buying | +4.2% | −40.9% | +28.7% |
| October 30, 2015 | 3 buying | −26.3% | −8.2% | −28.1% |